RNA
Avidity Biosciences, Inc. [RNA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RNA Stock Summary
Top 10 Correlated ETFs
RNA
Top 10 Correlated Stocks
RNA
In the News
RNA Financial details
Company Rating
Sell
Market Cap
1.92B
Income
-207.02M
Revenue
9.56M
Book val./share
6.58
Cash/share
7.83
Dividend
-
Dividend %
-
Employees
253
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.37
Forward P/E
-
PEG
3.45
P/S
83.78
P/B
1.64
P/C
2.87
P/FCF
-4.74
Quick Ratio
11.14
Current Ratio
11.4
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
-10.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
27.61%
Revenue last 5Y
32.75%
Revenue Q/Q
-22.18%
EPS Q/Q
11.27%
-
-
-
-
SMA20
-
SMA50
100%
SMA100
300%
Inst Own
91.66%
Inst Trans
0.78%
ROA
-34%
ROE
-35%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-2144%
Profit Margin
-1917%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.825-27.66
52W High
-16.87%
52W Low
+461.13%
RSI
46
Rel Volume
0.66
Avg Volume
1.19M
Volume
782.9K
Perf Week
-11.46%
Perf Month
4.59%
Perf Quarter
360.88%
Perf Half Y
270.99%
-
-
-
-
Beta
0.772
-
-
Volatility
0.56%, 1.26%
Prev Close
-2.58%
Price
22.445
Change
-4.69%
RNA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.31 | 0.23 | 0.18 | 0.13 | |
| Net income per share | -0.86 | -2.03 | -2.83 | -3.24 | -2.91 | |
| Operating cash flow per share | 0.07 | -1.71 | -2.29 | -2.61 | -1.63 | |
| Free cash flow per share | 0.06 | -1.76 | -2.38 | -2.67 | -1.69 | |
| Cash per share | 2.52 | 15.46 | 11.84 | 11.71 | 8.15 | |
| Book value per share | -1.74 | 14.14 | 9.21 | 11.08 | 6.86 | |
| Tangible book value per share | -1.74 | 14.14 | 9.21 | 11.08 | 6.86 | |
| Share holders equity per share | -1.74 | 14.14 | 9.21 | 11.08 | 6.86 | |
| Interest debt per share | 0.33 | -0.3 | 0.28 | 0.1 | 0.13 | |
| Market cap | 1.07B | 552.84M | 984.74M | 1.16B | 660.76M | |
| Enterprise value | 979.42M | 225.64M | 589.16M | 827.77M | 485.53M | |
| P/E ratio | -33.28 | -12.57 | -8.39 | -6.85 | -3.11 | |
| Price to sales ratio | 461 | 81.46 | 105.59 | 125.49 | 69.12 | |
| POCF ratio | 429.34 | -14.89 | -10.39 | -8.49 | -5.55 | |
| PFCF ratio | 474.08 | -14.47 | -9.99 | -8.32 | -5.36 | |
| P/B Ratio | -16.36 | 1.81 | 2.58 | 2 | 1.32 | |
| PTB ratio | -16.36 | 1.81 | 2.58 | 2 | 1.32 | |
| EV to sales | 422.34 | 33.25 | 63.17 | 89.74 | 50.79 | |
| Enterprise value over EBITDA | -57.67 | -5.1 | -4.99 | -4.63 | -2.08 | |
| EV to operating cash flow | 393.34 | -6.08 | -6.21 | -6.07 | -4.08 | |
| EV to free cash flow | 434.33 | -5.91 | -5.98 | -5.95 | -3.94 | |
| Earnings yield | -0.03 | -0.08 | -0.12 | -0.15 | -0.32 | |
| Free cash flow yield | 0 | -0.07 | -0.1 | -0.12 | -0.19 | |
| Debt to equity | -0.08 | -0.02 | 0.03 | 0.02 | 0.02 | |
| Debt to assets | 0.05 | -0.02 | 0.03 | 0.02 | 0.02 | |
| Net debt to EBITDA | 5.28 | 7.39 | 3.35 | 1.84 | 0.75 | |
| Current ratio | 9.35 | 22.74 | 13.86 | 12 | 7.58 | |
| Interest coverage | -2.35 | -211.85 | 0 | 31.44 | 0 | |
| Income quality | -0.1 | 0.84 | 0.8 | 0.78 | 0.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.01 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.2 | 1.98 | 2.81 | 4.09 | 5.67 | |
| Research and developement to revenue | 6.27 | 5.54 | 10.85 | 16.31 | 19.98 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.09 | 0.03 | 0.04 | 0.02 | 0.04 | |
| Capex to revenue | -0.1 | -0.16 | -0.4 | -0.31 | -0.44 | |
| Capex to depreciation | -0.68 | -2.93 | -5.85 | -2.04 | -2.01 | |
| Stock based compensation to revenue | 0.18 | 0.64 | 1.83 | 2.94 | 4 | |
| Graham number | 5.79 | 25.41 | 24.23 | 28.43 | 21.18 | |
| ROIC | 0.37 | -0.15 | -0.29 | -0.29 | -0.46 | |
| Return on tangible assets | -0.33 | -0.13 | -0.27 | -0.26 | -0.34 | |
| Graham Net | -1.79 | 14.19 | 10.73 | 10.57 | 6.42 | |
| Working capital | 85.44M | 317.09M | 381.48M | 571.03M | 530.63M | |
| Tangible asset value | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M | |
| Net current asset value | -66.59M | 304M | 364.99M | 562.22M | 483.52M | |
| Invested capital | -0.08 | -0.02 | 0.03 | 0.02 | 0.02 | |
| Average receivables | 400K | 1000K | 1.05M | 1.5M | 2M | |
| Average payables | 1.94M | 5.03M | 10.92M | 9.36M | 6.72M | |
| Average inventory | 0.5 | -600K | -1.05M | -450K | 0.5 | |
| Days sales outstanding | 125.92 | 64.54 | 35.22 | 83.1 | 72.73 | |
| Days payables outstanding | 57.94 | 75.18 | 8.05K | 1.22K | 1.53K | |
| Days of inventory on hand | 0 | -11.65 | -514.08 | 0 | 0 | |
| Receivables turnover | 2.9 | 5.66 | 10.36 | 4.39 | 5.02 | |
| Payables turnover | 6.3 | 4.86 | 0.05 | 0.3 | 0.24 | |
| Inventory turnover | 14.54M | -31.34 | -0.71 | 1.39M | 0 | |
| ROE | 0.49 | -0.14 | -0.31 | -0.29 | -0.42 | |
| Capex per share | -0.01 | -0.05 | -0.09 | -0.05 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Net income per share | -0.83 | -0.67 | -0.66 | -0.71 | -0.79 | |
| Operating cash flow per share | -0.68 | -0.7 | -0.7 | -0.5 | 0.22 | |
| Free cash flow per share | -0.7 | -0.72 | -0.71 | -0.51 | 0.21 | |
| Cash per share | 10.66 | 8.32 | 8.08 | 7.32 | 7.83 | |
| Book value per share | 10.09 | 7.94 | 7.83 | 6.98 | 6.58 | |
| Tangible book value per share | 10.09 | 7.94 | 7.83 | 6.98 | 6.58 | |
| Share holders equity per share | 10.09 | 7.94 | 7.83 | 6.98 | 6.58 | |
| Interest debt per share | 0.15 | 0.14 | 0.13 | 0.14 | 0.13 | |
| Market cap | 1.27B | 1.08B | 791.72M | 472.74M | 688.27M | |
| Enterprise value | 941.69M | 969.41M | 647.35M | 397.67M | 513.04M | |
| P/E ratio | -6.66 | -5.73 | -4.21 | -2.26 | -2.85 | |
| Price to sales ratio | 459.15 | 484.17 | 341.85 | 167.76 | 313.85 | |
| POCF ratio | -32.44 | -22.08 | -15.9 | -12.85 | 41.71 | |
| PFCF ratio | -31.75 | -21.29 | -15.7 | -12.53 | 44.01 | |
| P/B Ratio | 2.2 | 1.93 | 1.42 | 0.91 | 1.37 | |
| PTB ratio | 2.2 | 1.93 | 1.42 | 0.91 | 1.37 | |
| EV to sales | 340.08 | 434.13 | 279.51 | 141.12 | 233.94 | |
| Enterprise value over EBITDA | -17.69 | -16.83 | -12.42 | -6.85 | -7.76 | |
| EV to operating cash flow | -24.03 | -19.8 | -13 | -10.81 | 31.09 | |
| EV to free cash flow | -23.52 | -19.09 | -12.84 | -10.54 | 32.81 | |
| Earnings yield | -0.04 | -0.04 | -0.06 | -0.11 | -0.09 | |
| Free cash flow yield | -0.03 | -0.05 | -0.06 | -0.08 | 0.02 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Net debt to EBITDA | 6.19 | 1.94 | 2.77 | 1.29 | 2.65 | |
| Current ratio | 12 | 12.42 | 13.14 | 11.4 | 7.58 | |
| Interest coverage | 24.16 | 135 | 0 | 0 | 0 | |
| Income quality | 0.78 | 0.93 | 1.06 | 0.7 | -0.27 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.75 | 5.4 | 5.3 | 4.87 | 7.35 | |
| Research and developement to revenue | 16.47 | 21.39 | 18.42 | 16.93 | 24.08 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.04 | 0.01 | 0.03 | -0.05 | |
| Capex to revenue | -0.31 | -0.82 | -0.27 | -0.33 | -0.39 | |
| Capex to depreciation | -2.23 | -4.65 | -1.18 | -1.63 | -1.4 | |
| Stock based compensation to revenue | 2.64 | 4.08 | 4.08 | 3.48 | 4.49 | |
| Graham number | 13.75 | 10.94 | 10.77 | 10.54 | 10.85 | |
| ROIC | -0.08 | -0.08 | -0.08 | -0.1 | -0.13 | |
| Return on tangible assets | -0.07 | -0.08 | -0.08 | -0.09 | -0.1 | |
| Graham Net | 9.63 | 7.55 | 7.36 | 6.57 | 6.17 | |
| Working capital | 571.03M | 549.06M | 549.29M | 506.77M | 530.63M | |
| Tangible asset value | 578.08M | 558.92M | 559.18M | 517.47M | 500.76M | |
| Net current asset value | 562.22M | 542.09M | 542.93M | 499.79M | 483.52M | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 1.7M | 1.55M | 1.05M | 1.05M | 1.45M | |
| Average payables | 15.51M | 4.27M | 4.78M | 5.6M | 7.18M | |
| Average inventory | 1 | -500K | -1.05M | -1.05M | -500K | |
| Days sales outstanding | 68.26 | 40.3 | 42.75 | 31.94 | 78.18 | |
| Days payables outstanding | 1.1K | 325.97 | 403.47 | 384.23 | 1.29K | |
| Days of inventory on hand | 0 | -83.41 | -78.51 | -69.23 | 0 | |
| Receivables turnover | 1.32 | 2.23 | 2.11 | 2.82 | 1.15 | |
| Payables turnover | 0.08 | 0.28 | 0.22 | 0.23 | 0.07 | |
| Inventory turnover | 381K | -1.08 | -1.15 | -1.3 | 0 | |
| ROE | -0.08 | -0.08 | -0.08 | -0.1 | -0.12 | |
| Capex per share | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 |
RNA Frequently Asked Questions
What is Avidity Biosciences, Inc. stock symbol ?
Avidity Biosciences, Inc. is a US stock , located in San diego of Ca and trading under the symbol RNA
What is Avidity Biosciences, Inc. stock quote today ?
Avidity Biosciences, Inc. stock price is $22.445 today.
Is Avidity Biosciences, Inc. stock public?
Yes, Avidity Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.19M
- Market Capitalization 1.92B
- Employee 253
- CEO Ms. Sarah Boyce
- Headquarters San Diego,CA,US
- IPO Date 2020-06-12
-
Website
https://www.aviditybiosciences.com 
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
